CalciMedica (CALC) vs Longeveron (LGVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CalciMedica is the larger company by market cap ($8.7 million vs $7.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CALC | LGVN |
|---|---|---|
| Share price | $1.27 | $2.48 |
| Market cap | $8.67M | $7.91M |
| 1-day change | -2.31% | +4.64% |
| YTD return | -96.05% | — |
| 1-year return | -91.84% | — |
| EPS (TTM) | $-6.85 | $-9.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $36.00 | $12.30 |
| 52-week low | $1.27 | $2.30 |
| Distance from 52-week high | -96.47% | -79.84% |
| Analyst consensus | none | none |
| Avg. price target upside | +3837.01% | +2369.76% |
| Average volume | 75.54K | 92.38K |
| Shares outstanding | 6.83M | 3.04M |
| Employees | 15 | 38 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CalciMedica
CALC stock →CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Longeveron
LGVN stock →Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
CALC vs LGVN FAQ
Which is bigger, CalciMedica or Longeveron?
CalciMedica (CALC) is larger, with a market capitalization of $8.67M compared with $7.91M for Longeveron (LGVN).
Are CalciMedica and Longeveron in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.